Progress of bcl-2 inhibitors in treatment of plasma cell disorders with t(11;14)

VernacularTitle:bcl-2抑制剂治疗伴t（11；14）浆细胞病的研究进展
Author: Haibo YU ¹ ; Zhongxia HUANG
Author Information

1. 首都医科大学附属北京朝阳医院西院血液与肿瘤科，北京　100043
Keywords: Multiple myeloma; Leukemia, plasma cell; Light-chain; Genes, bcl-2
From: Journal of Leukemia & Lymphoma 2022;31(6):377-380
CountryChina
Language:Chinese
Abstract: Plasma cell disorders are a group of heterogeneous diseases originating from plasma cells, including multiple myeloma, plasma cell leukemia and light-chain amyloidosis, etc. Monoclonal plasma cells are detected in bone marrow and affected tissues, monoclonal immunoglobulin or components are detected in serum or urine, and some end-organs are injured. Plasma cell disorders accompanied by t(11;14) have unique biological characteristics and unsatisfactory response to proteasome inhibitors. With t(11;14) translocation, the expressions of cyclin D1 and anti-apoptotic protein bcl-2 are relatively high, which lead to the occurrence of plasma cell disorders and have implications for the prognosis of disease. Venetoclax is a bcl-2 inhibitor, and its single agent or combined with other drugs has achieved good efficacy in treatment of plasma cell disorders with t(11;14). This article reviews the progress of bcl-2 inhibitors in treatment of plasma cell disorders.